Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7798204 | 0.81 | HSD11B1 (0.44) | HSD11B1KDM4EL3MBTL1ALDH1A1HPGD | |
| SCHEMBL29506329 | 0.75 | HSD11B1 (0.91) | HSD11B1KDM4EL3MBTL1ALDH1A1HPGD | |
| SCHEMBL3486583 | 0.75 | HSD11B1 (0.91) | HSD11B1KDM4EL3MBTL1ALDH1A1HPGD | |
| SCHEMBL7798219 | 0.75 | HSD11B1 (0.49) | HSD11B1KDM4EL3MBTL1ALDH1A1HPGD | |
| SCHEMBL7798210 | 0.74 | KDM4E (0.57) | KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL3006653 | 0.73 | HSD11B1 (0.67) | HSD11B1KDM4EL3MBTL1ALDH1A1HPGD | |
| SCHEMBL3925050 | 0.73 | HSD11B1 (0.67) | HSD11B1KDM4EL3MBTL1ALDH1A1HPGD | |
| SCHEMBL5712482 | 0.68 | SMN1; SMN2 (0.41) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL27793875 | 0.68 | HSD11B1 (0.62) | HSD11B1KDM4EL3MBTL1ALDH1A1HPGD | |
| SCHEMBL14621509 | 0.68 | ALDH1A1 (0.60) | L3MBTL1ALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | ADGRF1, GPR174, CALCRL | HSD11B1 1728/4885KDM4E 4737/4885L3MBTL1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.